Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin

Fig. 2

Overall survival (OS) among patients with high and low ALC and NLR. ALC= absolute lymphocyte count; NLR= neutrophil to lymphocyte ratio; OS= Overall survival; 0=low; 1=high in (A) (B) (C) (D) (E) (F) (G) (H). OS of patients with high and low ALC at the baseline (A), 1month (B), 3-month (C) and 6-month test (D); OS of patients with high and low NLR at the baseline (E), 1- month (F), 3-month (G) and 6-month test (H)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us